Treatment advances in high-grade gliomas

被引：7

作者：

Chen, Xi ^{[1
]}

Cui, Yi ^{[2
]}

Zou, Liqun ^{[3
]}

机构：

[1] Sichuan Univ, Canc Ctr, Dept Radiotherapy, West China Hosp, Chengdu, Peoples R China

[2] Sichuan Univ, State Key Lab Biotherapy, Chengdu, Peoples R China

[3] Sichuan Univ, Canc Ctr, Dept Med Oncol, West China Hosp, Chengdu, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

high-grade gliomas; glioblastoma; cytotoxic chemotherapy; tumour treating fields; radiotherapy; targeted therapy; immunotherapy; RANDOMIZED PHASE-III; DEATH-LIGAND; LYMPHOCYTE-ACTIVATION GENE-3; NEWLY-DIAGNOSED GLIOBLASTOMA; CENTRAL-NERVOUS-SYSTEM; CAR-T-CELLS; RECURRENT GLIOBLASTOMA; IMMUNE CHECKPOINT; CANCER-IMMUNOTHERAPY; DOUBLE-BLIND;

D O I：

10.3389/fonc.2024.1287725

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-grade gliomas (HGG) pose significant challenges in modern tumour therapy due to the distinct biological properties and limitations of the blood-brain barrier. This review discusses recent advancements in HGG treatment, particularly in the context of immunotherapy and cellular therapy. Initially, treatment strategies focus on targeting tumour cells guided by the molecular characteristics of various gliomas, encompassing chemotherapy, radiotherapy and targeted therapy for enhanced precision. Additionally, technological enhancements are augmenting traditional treatment modalities. Furthermore, immunotherapy, emphasising comprehensive tumour management, has gained widespread attention. Immune checkpoint inhibitors, vaccines and CAR-T cells exhibit promising efficacy against recurrent HGG. Moreover, emerging therapies such as tumour treating fields (TTFields) offer additional treatment avenues for patients with HGG. The combination of diverse treatments holds promise for improving the prognosis of HGG, particularly in cases of recurrence.

引用

页数：19

共 207 条

[1] Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma [J].

Abbott, Rebecca C. ;

Iliopoulos, Melinda ;

Watson, Katherine A. ;

Arcucci, Valeria ;

Go, Margareta ;

Hughes-Parry, Hannah E. ;

Smith, Pete ;

Call, Melissa J. ;

Cross, Ryan S. ;

Jenkins, Misty R. .

CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2023, 12 (03)

[2] Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma [J].

Abbott, Rebecca C. ;

Verdon, Daniel J. ;

Gracey, Fiona M. ;

Hughes-Parry, Hannah E. ;

Iliopoulos, Melinda ;

Watson, Katherine A. ;

Mulazzani, Matthias ;

Luong, Kylie ;

D'Arcy, Colleen ;

Sullivan, Lucy C. ;

Kiefel, Ben R. ;

Cross, Ryan S. ;

Jenkins, Misty R. .

CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (05)

[3] HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial [J].

Ahmed, Nabil ;

Brawley, Vita ;

Hegde, Meenakshi ;

Bielamowicz, Kevin ;

Kalra, Mamta ;

Landi, Daniel ;

Robertson, Catherine ;

Gray, Tara L. ;

Diouf, Oumar ;

Wakefield, Amanda ;

Ghazi, Alexia ;

Gerken, Claudia ;

Yi, Zhongzhen ;

Ashoori, Aidin ;

Wu, Meng-Fen ;

Liu, Hao ;

Rooney, Cliona ;

Dotti, Gianpietro ;

Gee, Adrian ;

Su, Jack ;

Kew, Yvonne ;

Baskin, David ;

Zhang, Yi Jonathan ;

New, Pamela ;

Grilley, Bambi ;

Stojakovic, Milica ;

Hicks, John ;

Powell, Suzanne Z. ;

Brenner, Malcolm K. ;

Heslop, Helen E. ;

Grossman, Robert ;

Wels, Winfried S. ;

Gottschalk, Stephen .

JAMA ONCOLOGY, 2017, 3 (08) :1094-1101

[4] HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors [J].

Ahmed, Nabil ;

Salsman, Vita S. ;

Kew, Yvonne ;

Shaffer, Donald ;

Powell, Suzanne ;

Zhang, Yi J. ;

Grossman, Robert G. ;

Heslop, Helen E. ;

Gottschalk, Stephen .

CLINICAL CANCER RESEARCH, 2010, 16 (02) :474-485

[5] Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication [J].

Ali, Omar A. ;

Lewin, Sarah A. ;

Dranoff, Glenn ;

Mooney, David J. .

CANCER IMMUNOLOGY RESEARCH, 2016, 4 (02) :95-100

[6] Anti-angiogenic therapy for high-grade glioma (Review) [J].

Ameratunga, Malaka ;

Pavlakis, Nick ;

Wheeler, Helen ;

Grant, Robin ;

Simes, John ;

Khasraw, Mustafa .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (11)

[7] Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1 [J].

An, Zhijing ;

Hu, Yi ;

Bai, Yue ;

Zhang, Can ;

Xu, Chang ;

Kang, Xun ;

Yang, Shoubo ;

Li, Wenbin ;

Zhong, Xiaosong .

ONCOIMMUNOLOGY, 2021, 10 (01)

[8] Tim-3, a negative regulator of anti-tumor immunity [J].

Anderson, Ana Carrizosa .

CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (02) :213-216

[9] LAG3 (CD223) as a cancer immunotherapy target [J].

Andrews, Lawrence P. ;

Marciscano, Ariel E. ;

Drake, Charles G. ;

Vignali, Dario A. A. .

IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :80-96

[10] PD-1 blockade enhances the vaccination-induced immune response in glioma [J].

Antonios, Joseph P. ;

Soto, Horacio ;

Everson, Richard G. ;

Orpilla, Joey ;

Moughon, Diana ;

Shin, Namjo ;

Sedighim, Shaina ;

Yong, William H. ;

Li, Gang ;

Cloughesy, Timothy F. ;

Liau, Linda M. ;

Prins, Robert M. .

JCI INSIGHT, 2016, 1 (10)

← 1 2 3 4 5 6 7 8 9 10 →